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Objectives: To evaluate the function of the oculomotor and vestibular systems and to 
correlate these findings with the clinical status of patients with Gaucher disease type 3 
(GD3). The goal of this cross-sectional and longitudinal study was to find oculomotor 
biomarkers for future clinical trials.
Methods: Twenty-six patients with GD3 were assessed for eligibility and 21 were able 
to perform at least one task. Horizontal and vertical reflexive saccades, smooth pursuit, 
gaze-holding, optokinetic nystagmus, and horizontal vestibulo-ocular reflex (VOR) were 
examined by video-oculography/video-head impulse test and compared concurrently 
with 33 healthy controls. The Scale for the Assessment and Rating of Ataxia (SARA), the 
modified Severity Scoring Tool (mSST), and Grooved Pegboard Test (GPT) were admin-
istered to assess overall neurological function. Eleven patients were also re-assessed 
after 1 year.
results: Nine out of 17 patients exhibited gaze-holding deficits. One patient had upbeat 
nystagmus. Three patients presented with bilateral abducens palsy in combination
with central oculomotor disorders, suggesting a bilateral involvement of the abducens 
nucleus. Horizontal angular VOR gain was reduced in all patients (0.66 ± 0.37) compared 
with controls (1.1 ± 0.11, p < 0.001). Most strongly correlated with clinical rating scales 
were peak velocity of downward saccades (SARA: ρ = −0.752, p <  0.0005; mSST: 
ρ = −0.611, p = 0.003; GPT: ρ = −0.649, p = 0.005) and duration of vertical saccades 
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(SARA: ρ = 0.806, p < 0.001; mSST: ρ = 0.700, p < 0.0005; GPT: ρ = 0.558, p = 0.02) 
together with the VOR gain (SARA: ρ = −0.63, p = 0.016; mSST: ρ = −0.725, p = 0.003; 
GPT: ρ = −0.666, p = 0.004). Vertical smooth pursuit gain decreased significantly at 
follow-up.
interpretation: This study shows neuronal degeneration of the brainstem and cerebel-
lum with combined involvement of both supranuclear and nuclear oculomotor structures 
and the vestibular system in GD3. We also identified oculomotor parameters that cor-
relate with the neurological status and can be used as biomarkers in future clinical trials.
Keywords: gaucher disease type 3, neuronopathic gaucher disease, metabolic disease (inherited), neuro-
ophthalmology, ocular motility, saccades, horizontal supranuclear saccade palsy, vertical supranuclear saccade 
palsy
Abbreviations: CI, confidence interval; INC, interstitial nucleus of Cajal; HC, 
healthy controls; GD3, Gaucher disease type 3; GPT, Grooved Pegboard Test; mSST, 
modified severity scoring tool; OKN, optokinetic nystagmus; PPRF, paramedian 
pontine reticular formation; PV, peak velocity; riMLF, rostral interstitial nucleus 
of the medial longitudinal fascicle; SPV, slow-phase velocity; QPV, quick-phase 
velocity; VOR, vestibulo-ocular reflex; SARA, scale for the assessment and rating 
of ataxia; vHIT, video-head impulse test.
inTrODUcTiOn
Gaucher disease (GD) is an autosomal recessive lysosomal 
storage disease caused by a deficiency of the acid β-glucosidase, 
leading to glucosylceramide accumulation, primarily in the 
liver, spleen, and bone marrow (1). Chronic neuronopathic GD 
(type 3, GD3) is a Gaucher subtype characterized by progressive 
neurological manifestations associated with glycolipid accumu-
lation in the CNS (2, 3).
The disease has a variable clinical picture, but all GD3 
patients exhibit slowing of horizontal saccades leading to 
complete horizontal saccadic palsy. As the disease progresses, 
vertical saccades also become slower (1, 4). As horizontal and 
later vertical saccades are highly impaired early in the course of 
the disease, they were used as a primary endpoint to investigate 
treatment with miglustat (5). A study of two siblings with GD3 
suggested that the vestibulo-ocular reflex (VOR) might also be 
impaired in GD3 patients (6). Although saccadic eye movement 
abnormalities have been described, a comprehensive study of 
all forms of eye movements in GD3, including pursuit and 
vestibular-related movements in a large cohort of GD3 patients, 
has not been published yet.
Therefore, we performed a systematic examination of the 
oculomotor and vestibular function in GD3 patients, including 
a follow-up after 1 year, with the additional aim to find surrogate 
biomarkers for future clinical trials.
sUBJecTs anD MeThODs
subjects
We conducted a prospective multicenter cohort study. Twenty-
six patients from Germany, France, and the Czech Republic were 
screened for eligibility to participate in the study. Twenty-one 
patients (11 females) with genetically and clinically confirmed 
GD3, with a mean age of 17.89 ± 10.98 years (age ± SD), mean 
disease duration of 17.4 ± 12 years, and mean age at disease onset 
of 3.7 ± 5 years, who were able to perform at least one study task 
were included in this study.
Patients’ characteristics and correlations of clinical and oculo-
motor outcomes are listed in Table 1 and Table S1 in Supplementary 
Material. Eleven patients were assessed at two time points (longitu-
dinal analysis over 12 months). In these patients, data from the last 
visit of patients were used (Table S1 in Supplementary Material).
Thirty-three matched healthy individuals (19 females, 
18.69 ±  9.42  years) were also examined. All participants gave 
informed consent according to the Declaration of Helsinki. The 
study was approved by the local institutional review boards.
Methods
Eye movements were recorded using a video-based eye-tracker 
system, with the camera mounted on the left eye [EyeSeeCam® 
(7)] and examined as follows.
Saccades
Subjects made reflexive vertical and horizontal prosaccades in 
response to stimuli of 1.33° visual angle. Vertical saccades were 
elicited by stimuli of 5°, 10°, and 20° amplitude over the range 
±10° from the central position. Horizontal saccades of 5°, 15°, 
and 30° amplitude, at a range of ±15° from the central position, 
were required. Participants performed seven saccades in response 
to the stimulus of each size along both axes. The targets were 
presented in pseudorandom order for 2,500 ms with additional 
variation of 500 ms. Patients were provided with verbal encour-
agement to follow the target jumps and, for patients with more 
advanced disease, the investigator, or administering care giver, 
pointed to target locations. Patients were instructed not to blink 
during the saccadic performance, and if they do so, then during 
the fixation period.
Smooth Pursuit
After the initial fixation period of 2 s, the target subtending visual 
angle of 0.57° moved in 3 cycles at 0.1 and 3 cycles at 0.2  Hz 
frequencies, yielding peak target velocities of 9.5°/s and 18.8°/s 
horizontally and 6.4°/s and 12.6°/s vertically with ±15° amplitude 
horizontally (right and left) from the central position, and then 
±10° vertically (up and down) from the central position without 
TaBle 1 | Patients’ characteristics.
Patient 
no.
age of onset/
age of diagnosis 
(years)
First symptom 
observed, age 
(years)
Medication genotype neurologic and 
psychiatric findings
systemic manifestation  
and other findings
Mri  
findings
Ophthalmologic and clinical 
oculomotor findings
iQ
PaTienTs FOllOweD UP lOngiTUDinally
1 1/1 Oculomotor 
disturbance (not 
specified), 19
Imiglucerase 3,200 
U/2 weeks, eliglustat  
100 mg/day, spironolactone 
150 mg/day, calcium 
1,500 mg/day, potassium 
7,200 mg/day, magnesium 
450 mg/day, vitamin D  
3,000 U/day, pantoprazole  
40 mg/day
GBA:
W5333X
S384F + R535C
Hyperreflexibility, pyramidal 
signs, clonus, stance and  
gait ataxia, dystonia
Fixed kyphosis N Alternating convergent squint 
operatively corrected, bilaterally, 
persisting esotropia R, visual 
acuity 0.5 R, 1.0 L, horizontal 
saccade paresis, slow vertical 
saccades down > up, impaired 
horizontal > vertical OKN, 
bilaterally impaired VOR
79
2 0/0 Retarded motor 
development, 
Oculomotor 
disturbance  
(not specified), 16
Imiglucerase 2,000 
U/2 weeks
GBA:
L444P
L444P
Discrete stance and 
gait ataxia, dysmetria, 
hyperreflexibility, cognitive 
impairment
Hepatosplenomegaly,  
chronic obstructive lung 
disease
NP Alternating convergent squint, 
visual acuity 0.8 R, 0.8 L, 
abducens palsy bilaterally, slow 
saccades horizontal > vertical, 
smooth pursuit impaired 
vertical > horizontal, horizontal 
impaired OKN, impaired VOR 
bilaterally
68
3a 1/1 Oculomotor 
disturbance  
(not specified), 2
Imiglucerase 1,600 
U/2 weeks
GBA:
L444P
L444P
Dystonia Discrete hepatomegaly, 
chronic obstructive lung 
disease, bronchial asthma, 
atopic dermatitis, lactose 
intolerance
N Slow horizontal saccades, 
impaired horizontal OKN,  
discrete impaired VOR
101
4a 1/1 Oculomotor 
disturbance  
(not specified), 2
Imiglucerase 2,000 
U/2 weeks
GBA:
L444P
L444P
Hyperreflexibility, hypotonus 
of lower extremities
Chronic obstructive lung 
disease, discrete thoracic 
kyphosis, hepatomegaly, 
neurodermatitis
N Visual acuity 1.0 R, 1.0 L, slow 
horizontal saccades with curved 
trajectory (“around the house 
sign”), impaired horizontal OKN, 
discrete impaired VOR
105
5b 1/1 Oculomotor 
disturbance (not 
specified), 6
Imiglucerase  
800 U/2 weeks
GBA:
L444P
D409H
N Gibbus NP Visual acuity 1.0 R, 1.0 L, slow 
horizontal saccades, impaired 
horizontal OKN, impaired VOR
108
6b 7/7 NK Imiglucerase 2,400 
U/2 weeks
GBA:
L444P
D409H
Mild cognitive impairment Mild chronic obstructive  
lung disease
Discrete 
unspecific 
white matter 
changes
Visual acuity 1.0 R, 0.8 L, low 
horizontal saccades, slow 
downward vertical saccades, 
impaired horizontal OKN,  
discrete impaired VOR
85
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Patient 
no.
age of onset/
age of diagnosis 
(years)
First symptom 
observed, age 
(years)
Medication genotype neurologic and 
psychiatric findings
systemic manifestation  
and other findings
Mri  
findings
Ophthalmologic and clinical 
oculomotor findings
iQ
7 6/33 Oculomotor 
disturbance  
(not specified), 30 
Epilepsy, 10
Imiglucerase 2,800 
U/2 weeks, zonisamide 
100 mg 2-0-3, citalopram 
20 mg 1-0-0, clonazepam 
0,5 mg 1/2-0-1, valproate 
300 mg 1-0-2
GBA:
G202R
D409H
Stance and gait ataxia, 
epilepsy, myoclonus, 
spasticity, psychotic 
symptoms
Hepatomegaly, obstructive 
sleep-apnea syndrome, 
neurodermatitis
Unspecific 
white matter 
changes
Visual acuity 0.8 R, 0.8 L, 
horizontal saccade paresis L > R, 
slow abduction > adduction 
bilaterally, prolonged latency of 
horizontal saccades, slow vertical 
saccades, mild impaired smooth 
pursuit, impaired horizontal OKN
71
8 2/2 Retarded motor 
development, 
29, Oculomotor 
disturbance (not 
specified)
Imiglucerase 3,200 
U/2 weeks, levetiracetam 
3,000 mg/day, lamotrigine 
200 mg/day oxcarbazepine 
2,400 mg/day
GBA:
L444P
L444P
Epilepsy, cognitive 
impairment, dystonia,  
stance and gait ataxia, 
pyramidal signs, clonus 
bilateral, hypomimia
St.p. spleen resection, femoral 
head necrosis, pathological 
right femur fracture, fixed 
kyphosis, restrictive lung 
disease
Discrete 
ventricle 
enlargement
Visual acuity 0.63 R, 0.63 L, 
horizontal saccade paresis, 
impaired horizontal OKN
68
9c 1/1 Retarded motor 
development, 
16, Oculomotor 
disturbance (not 
specified)
Imiglucerase 4,400 
U/2 weeks
GBA:
L444P
L444P
Stance and gait ataxia, 
spasticity, hyperreflexibility, 
dysarthria, dystonia, 
cognitive impairment
Fixed kyphosis N Slow horizontal saccades, slow 
downward vertical saccades, 
impaired horizontal and downward 
OKN, impaired VOR, head thrusts, 
operatively corrected squint, 
abducens palsy bilaterally R > L
60
10c 0/prenatal Retarded motor 
development, 
8, Oculomotor 
disturbance (not 
specified)
Imiglucerase 2,000 
U/2 weeks
GBA:
L444P
L444P
Stance and gait ataxia, 
hyperreflexibility, dystonia, 
dysarthria, discrete cognitive 
impairment
Gibbus NP Operatively corrected squint 
R, esotropia R, visual acuity 
0.8 R, 1.0 L, complete bilateral 
abducens palsy, primary position 
upbeat nystagmus, horizontal and 
vertical slow saccades, impaired 
horizontal smooth pursuit, 
impaired horizontal OKN, bilateral 
impaired VOR, head thrusts
60
11b 7/7 NK Imiglucerase 2,000 
U/2 weeks
GBA:
L444P
D409H
N N N Visual acuity 1.0 R, 0.63 L, low 
horizontal saccades, discrete slow 
downward vertical saccades, 
impaired horizontal OKN, discrete 
impaired vertical smooth pursuit, 
discrete head thrusts
111
PaTienTs MeasUreD aT 1 TiMePOinT
Patient 
no./ 
sex/age
age of onset/ 
age diagnosis
First symptom 
observed, age 
(years)
Medication genotype neurologic and 
psychiatric findings
internal manifestation Mri findings Oculomotor findings 
(pathological)
iQ
12 6 months/4 Oculomotor 
disturbance,  
6 months
Imiglucerase 2,400 
U/2 weeks
GBA:
L444P
L444P
N Hepatosplenomegaly, chronic 
obstructive lung disease
N Slow horizontal saccades 
with looping, impaired VOR 
leftward > rightward, impaired 
horizontal OKN
131
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Patient 
no./ 
sex/age
age of onset/ 
age diagnosis
First symptom 
observed, age 
(years)
Medication genotype neurologic and 
psychiatric findings
internal manifestation Mri findings Oculomotor findings 
(pathological)
iQ
13 21/21 Epilepsy, 15 Imiglucerase 3,200 
U/2 weeks, lamotrigine 
600 mg/day, levetiracetam 
1,000 mg/day, 10 gtt 
salbutamol, dimethindene 
4 mL/day
GBA:
N227S
L424P
Epilepsy Osteomyelofibrosis 
with trombocytopenia, 
neurodermatitis, allergic 
reaction on the imiglucerase 
therapy
N Visual acuity 1.0 R, 1.0 L, discrete 
slow horizontal saccades, 
saccadic vertical smooth pursuit
114
14 6/10 Oculomotor 
disturbance, 6
Imiglucerase 3,400 
U/2 weeks
GBA:
IVS2 + 1G > A
R463C
N Hashimoto thyroiditis, 
hepatosplenomegaly
St. p. 
petrous bone 
cholesterol 
granuloma 
removal
Visual acuity 1.0 R, 0.63 L, 
slow horizontal saccades with 
“looping,” borderline slow vertical 
saccades, pathological VOR
124
15 2/4 Hepatosplenomegaly 
4, Oculomotor 
disturbance, 8
Imiglucerase 2,800 U/kg GBA:
L335V
L335V
Postural and extremity 
cerebellar ataxia,  
hypotonus, dyscalculia
Mild hepatosplenomegaly Hypointensities 
in pallidum and 
thalamus
Visual acuity 0.63 R, 0.63 L, 
ptosis L with a Cogan-Twitch, 
abduction deficit L > R, abnormal 
smooth pursuit with “looping” 
upwards, horizontal slow 
abducting > adducting saccades, 
vertical slow saccades with 
“looping,” mild head thrusts, 
horizontal OKN present, but 
saccades impaired, impaired VOR 
with extremely slow compensatory 
eye movement, intact visual 
fixation-suppression of the VOR
81
16 1 month/ 
17 months
Hepatosplenomegaly, 
1 month
Velaglucerase 1,600 
U/2 weeks
GBA:
R359Q
RecΔ55
N Hepatosplenomegaly, 
generalized lymphadeno-
pathy, hypotrophic habitus, 
trombocytopenia, neonatal 
ikterus, atopic eczema, 
ichtyosis simplex, st. p. 
anaphylactic reaction after 
the ninth dose of enzymatic 
therapy
NP Visual acuity 0.7 bilaterally, 
impaired smooth pursuit 
vertically > horizontally, borderline 
impaired horizontal saccades
NP
17 6 months/ 
6 months
Hepatosplenomegaly, 
6 months
Imiglucerase 2,800 
U/2 weeks, carbamazepine 
900 mg/day, valproate 
500 mg/day
GBA:
L444P
L444P
Epilepsy with a complex 
symptomatology,  
myoclonia, dyscalculia
Hepatosplenomegaly,  
gibbus, osteopenia, 
kyphoscoliosis with a 
thoracolumbar deformity
N St. p. partial vitrectomy R, 
visual acuity 0.5 R, 0.8 L, low 
horizontal and downward vertical 
saccades, impaired vertical 
smooth pursuit, decreased 
vertical OKN, pathological VOR 
leftward > rightward
MoCA: 
28/30
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Patient 
no./ 
sex/age
age of onset/ 
age diagnosis
First symptom 
observed, age 
(years)
Medication genotype neurologic and 
psychiatric findings
internal manifestation Mri findings Oculomotor findings 
(pathological)
iQ
18 7/7 Oculomotor 
disturbance, 7
Epilepsy, 22
Imiglucerase 60 U/
kg/2 weeks
GBA:
L444PRecTL
Epilepsy, anxiety attacks, 
generalized hyperreflexia, 
discrete spasticity with 
positive Babinsky and 
slow rapid movements 
on the right foot, anxiety, 
depression
– Medullary 
infiltration of  
the pontine, 
basin, femoral 
and tibial  
bones 
bilaterally
Convergent strabismus, 
anamnestic initially complete 
horizontal saccade palsy, at 
the time of examination slow 
horizontal saccades performable, 
bilateral abducens palsy, slow 
upward saccades, downward 
saccade palsy, blinking
NP
19 18/1 Diagnosis established 
on the basis of the 
diagnosis of his 
sister, first symptoms 
appeared at age 18
No therapy GBA:
L444PRecTL
Manic behavior, anxiety  
and depression
Splenomegaly Medullary 
infiltration of 
the spine
Convergent strabismus, slow 
horizontal and downward 
saccades, pathological VOR
NP
20 3/19 NK Imiglucerase, levetiracetam GBA:
L444P
L444P
Epilepsy, facial dystonia, 
nasal speech, wide-based 
gait
Scoliosis, splenectomy due 
to spleen rupture, interstitial 
lung disease, abnormal bone 
marrow findings in MRI
NP Convergent strabismus, 
pathological VOR
NP
21 12/27 Epilepsy, 12 Miglustat 300 mg/day, 
valproic acid 2,000 mg/day, 
clonazepam, bromazepam, 
phenobarbital 200 mg/day, 
zonisamide
GBA:
L444P
D409H
Becker disease, axonal 
neuropathy, myoclonic 
epilepsy, mild facial  
dystonia, tremor, extremity 
ataxia, hyperreflexia, 
no Babinski, no muscle 
weakness
Moderate 
hepatosplenomegaly, scoliosis, 
uncle and brother suffer from 
Becker’s muscular dystrophy
NP Horizontal supranuclear saccade 
palsy with blinking and head 
thrusts
NP
22 1/1 Hepatospleno-
megaly, 1
Imiglucerase 60 U/kg, 
carbamazepine, paroxetine, 
valium 60 U/kg, baclofen
GBA:
L444P
D409H
Myoclonic epilepsy, difficulty 
opening mouth, wide- 
based gait, axial and 
extremity ataxia, facial 
dystonia with dystonic 
tremor, hyperreflexia, no 
Babinski, high arches, 
hammer toes, mild lower 
extremity dysmetria, 
depression, paroxysmal 
aggression
Kyphosis, bone pain Normal MRI Convergent strabismus NP
23 13 months/ 
13 months
Hepatos-
plenomegaly, 2
Velaglucerase alfa 60 U/kg GBA:
D409H
D409H
– Hepatosplenomegaly, Turkish 
origin, two uncles of his father 
died of Gaucher disease
NP Horizontal supranuclear saccade 
palsy with blinking
NP
24 1 month/ 
18 months
Stridor and early 
psychomotor  
delay, 1 month
Imiglucerase GBA:
D409H
IVS2 + 1G > A
Early psychomotor delay, 
walking not possible, can 
stand up with support, 
facial, cervical and 
acromioclavicular dystonia
Hepatosplenomegaly,  
stridor (diminishing under 
the therapy) from birth on, 
Cambodian origin. BAER 
abnormal with normal hearing
NP Complete gaze palsy, convergent 
strabismus
NP
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Patient 
no./ 
sex/age
age of onset/ 
age diagnosis
First symptom 
observed, age 
(years)
Medication genotype neurologic and 
psychiatric findings
internal manifestation Mri findings Oculomotor findings 
(pathological)
iQ
25 18 months/ 
3 years
Early developmental 
delay 18 months, 
stance and gait 
ataxia, 5
Ambroxol 80 mg/day GBA:
R163X
I260T
Myokimia, myoclonus, 
dystonia, startle, cloni, 
loss of walking ability with 
instability and sudden falls. 
Loss of speech
Nigerian origin. 
Hepatosplenomegaly, iron 
deficiency, thalassemia minor, 
microcytic anemia. Under 
therapy with imiglucerase 
worsening of ataxia, speech 
and myoclonic epilepsy with 
a progressive deterioration. 
Anamnestic reported 
improvement of the speech 
(saying words such as  
Maman or Au revoir), fine 
(playing with toys) and gross 
motor function (walking)
NP Complete gaze palsy with 
convergent bilateral esotropia, 
abducens nerve palsy bilaterally
NP
26 1 month/1 year Stridor and early 
developmental delay, 
11 months
Ambroxol 40 mg/day GBA:
G377S
c.141ΔAG
Developmental delay, 
gross motor impairment, 
dysphagia with growth 
retardation
Algerian origin. 
Hepatosplenomegaly, 
bronchial congestion with 
chronic stridor and cough
NP Convergent squint NP
BAER, brainstem acoustic evoked responses; L, left; N, normal findings; NK, not known; NP, not performed; MRI, magnetic resonance imaging; MoCA, Montreal Cognitive Assessment; OKN, optokinetic nystagmus, R, right; VOR, 
vestibulo-ocular reflex.
a,b,cIndicated patients are siblings.
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a break. Smooth pursuit gain was calculated as the ratio of slow-
phase eye velocity (SPV) to target velocity.
Gaze-Holding
Participants were asked to fixate a point of 0.57° visual angle 
presented on a monitor without moving their head. The point 
was primarily positioned at eye level to allow fixation straight 
ahead, then eccentricity changed from 15° left to 15° right and 
10° down. The stimulus was presented for 10 s at each position. 
The data analysis of slow and quick phases of the gaze-holding 
nystagmus and drift was performed, as described previously 
(8–10). Frequency, peak velocity (PV), and amplitude of the 2D 
vector of quick phases were analyzed.
Optokinetic Nystagmus
The stimulus field subtended the visual angle of 28°. The stimulus 
consisted of alternating black-and-white stripes that moved for 
15 s at a velocity of 7°/s with a white stripe of 0.67° and a black 
stripe of 0.29° moving to the left and to the right. Prior to each 
examination, a white point was presented in the primary position 
for 3 s. Subjects were instructed to keep gazing into the center of 
the pattern, to try to maintain optimal clarity of the stripes, and 
not to follow any one stripe deliberately.
Angular Horizontal VOR
Head impulses were defined based on the following criteria: 1. 
peak angular head velocity reached within the first 150 ms after 
onset of head impulse, 2. peak angular head velocity exceeded 
100°/s, 3. head acceleration exceeded 1,000°/s2, and 4. head 
velocity 50 ms before onset of the impulse did not exceed 20°/s. 
The relevant component of head velocity cannot change sign 
during the impulse. Head impulses with a maximum head 
velocity outside 1.5-fold the interquartile range were rejected 
as outliers. A vector analysis of the three-dimensional input– 
output kinematics of the aVOR during high-acceleration rota-
tions was expressed as gain γ (11). Participants were instructed 
to fixate a white point of visual angle of 0.3° positioned in the 
center of the monitor. 10 ± 2 head impulses were performed to 
each side.
Disease Evaluation
The overall neurological function in the GD3 patients was 
assessed by the modified Severity Scoring Tool (mSST) (12). 
Cerebellar status was evaluated by the Scale for Assessment 
and Rating of Ataxia (SARA) (13). Visuo-manual coordination 
was examined by means of the Grooved Pegboard Test (GPT). 
Cognition was assessed by the Wechsler Adult Intelligence Scale-
Revised and the Wechsler Intelligence Scale for Children-IV 
(14) (WISC-IV).
statistical analysis
We report mean, SD, and 95% confidence interval for continu-
ous, absolute, and relative frequencies for categorical variables. 
Normality of data distribution was tested using the mean, median, 
SD, skewness, kurtosis, and box plots. As data were not normally 
distributed, related-samples Wilcoxon signed-rank test was run 
to determine if there were differences in measured scores between 
the initial examination and follow-up after 1  year. Non-paired 
Mann–Whitney U-tests were used to compare patients and 
healthy controls. For the group analysis, data from the follow-up 
visit of patients measured twice were used. For the longitudinal 
analysis, outcomes of 11 patients measured at two timepoints 
1 year apart were compared. The two-tailed significance level was 
0.05. As this is an exploratory study, no correction for multiple 
testing was conducted.
To assess the strength of the relationships between tested 
variables, Spearman’s rank correlation coefficient ρ was calcu-
lated. Patients with missing data in the outcome were excluded. 
Statistical analysis and figure design were performed using SPSS 
version 23.0.0 (IBM, New York, NY, USA).
resUlTs
Ocular Motor system
Representative raw data of oculomotor systems of patient 17 are 
shown in Figures 1A–E.
Saccades
Mean asymptotic PV of both horizontal and vertical saccades 
in response to stimulus of 30° was 120.97°/s (83, [83.2–158.8]) 
(mean (±SD, [95% CIs of the mean])) in patients and 463.1°/s 
(77.1, [434.8–491.4]) in controls (p  <  0.001). Mean latency 
was 0.269  s (0.13, [0.21–0.33]) in patients and 0.185  s (0.08, 
[0.157–0.213]) in controls (p = 0.01). Mean duration was 0.65 s 
(0.322, [0.5–0.79]) in patients and 0.13 s (0.04, [0.12–0.15]) in 
controls (p < 0.001). Mean gain was 0.57 (0.3, [0.44–0.71]) in 
patients and 0.88 (0.07, [0.85–0.9]) in the control group, respec-
tively (p < 0.001). Measures of abducting vs. adducting saccades 
were not significantly different (Table S2 in Supplementary 
Material).
Mean asymptotic PV of vertical saccades in response to a 
stimulus of 20° was 209.7°/s (128.9, [151–268.4]) in patients and 
344.5°/s (67.6, [320.9–368.1]) in controls (p < 0.001). Mean latency 
was 0.237  s (0.111, [0.187–0.287]) in GD3 and 0.198  s (0.086, 
[0.168–0.228]) in normal controls, respectively (p = 0.053). Mean 
duration was 0.39  s (0.34, [0.24–0.55]) in patients and 0.12  s 
(0.03, [0.12–0.13]) in controls (p < 0.001). Mean gain of vertical 
saccades was 0.73 (0.23, [0.63–0.83]) in patients and 0.79 (0.11, 
[0.75–0.83]) in controls (p = 0.544).
To assess overall saccadic performance compared to previ-
ous studies (4, 5), slopes of peak duration vs. amplitude were 
calculated by linear regression fit of the saccades. Slopes of 
horizontal saccades were 9.04 (10, [4.49–13.6]) in patients 
and 1.58 (0.5, [1.4–1.76]) in controls (p < 0.001). The slopes of 
peak duration vs. amplitude for vertical saccades were 6.9 (13, 
[0.98–12.8]) in patients and 1.9 (0.79, [1.6–2.2]) in the control 
group, respectively (p < 0.01). The slopes of peak duration vs. 
amplitude for downward vertical saccades were 10.58 (17.75, 
[2–19.1]) in patients and 2.19 (1.05, [1.81–2.6]) in the control 
group, respectively (p =  0.005). The slopes of peak duration 
vs. amplitude for upward vertical saccades were 5.43 (10.8, 
[0.5–10.34]) in patients and 1.71 (0.64, [1.47–1.95]) in the 
control group, respectively (p < 0.05).
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FigUre 1 | Representative raw data of oculomotor systems. A representative overview of oculomotor systems in a patient with GD3 (patient 17) and in gaze-
holding in a patient with upbeat nystagmus (patient 10). Blue lines indicate a horizontal eye movement and red lines a vertical eye movement. Horizontal saccades 
are remarkably slow and hypometric, whereas vertical saccades are almost intact (a). In contrast, horizontal smooth pursuit has a higher gain than the vertical 
smooth pursuit (B). Horizontal optokinetic nystagmus is absent, vertical present (c). The gaze-holding plot demonstrates a nystagmus-like eye movement drift, 
resembling saccadic pulses, which is more pronounced in the vertical plane (D). Note that these pathological eye movements are present also during the saccadic 
and smooth pursuit examination (a,B). Raw data of horizontal and vertical gaze-holding of a patient with upbeat nystagmus (e). Horizontal (upper trace) and vertical 
(lower trace) eye movements.
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To investigate which saccadic parameters most reflect 
neurological status, correlation analysis between clinical rating 
scales and saccadic measures was performed. PV of downward 
saccades and duration of vertical saccades showed the strong-
est associations with all applied clinical parameters (Table  2; 
Figures 2A–C). Other measures of downward vertical saccades, 
such as duration, amplitude, and slopes, also showed variable but 
significant associations with clinical scores. This was also true for 
all measures of vertical saccades and all clinical measures. Slopes 
of horizontal and vertical upward saccades showed no significant 
relationships with any of the clinical measures, but the IQ score 
(vertical slopes) was highly correlated with all clinical rating 
scales (Table 2). There was no significant relationship between 
horizontal and vertical saccadic slopes. Age was not related to 
saccadic performance.
Smooth Pursuit
Since smooth pursuit matures until mid-adolescence (15, 16), 
children aged 4–16 and adults older than 16 were analyzed 
separately. This maturing process was also observed in a sig-
nificant association between age and vertical smooth pursuit 
(upward  >  downward, Table  2). Table S2 in Supplementary 
Material provides an overview of smooth pursuit values. 
Downward gain at 0.1  Hz differed significantly between adult 
patients and controls (p = 0.013).
There was no difference between smooth pursuit to the left 
and the right, but there was a significant difference between 
upward and downward smooth pursuit at both frequencies in 
both pediatric and adult patients. Interestingly, this was also 
true for adult controls at 0.1  Hz. Correlation analysis showed 
a significant relationship between downward smooth pursuit 
at 0.1 Hz and mSST and SARA scores. The horizontal smooth 
pursuit was negatively associated with GPT z-scores of both 
hands (Table 2).
Gaze-Holding Function
Slow-Phase Velocity of Gaze-Holding Nystagmus
Nine out of 17 patients exhibited gaze-holding deficits. Patient 
10 had primary-position upbeat nystagmus (Figure 1E). SPV 
of the horizontal eye movement drift with the gaze straight 
ahead differed significantly, yielding 0.48°/s (0.57 [0.19–0.77]) 
(mean (±SD [95% CIs of the mean])) in patients and −0.01°/s 
(0.09 [−0.06–0.04]) in controls (p = 0.001). SPV of the vertical 
eye movement drift in the central position was significantly 
different with −0.64°/s (0.74 [−0.26, −1.02]) in patients 
and -0.03°/s (0.1 [−0.09, −0.02]) in controls (p  <  0.001) 
(Figure 3A). Gaze-holding deficits were most pronounced in 
patients 1, 3, 7, 17, and 21, as was SPV of the gaze-holding nys-
tagmus in every examined position, in vertical and horizontal 
directions (Table S2 in Supplementary Material). In terms of 
correlations between neurological function and gaze-holding, 
vertical eye movement drift in the center and in the down 
position correlated significantly with all clinical tests applied, 
except bimanual GPT z-scores in the down position (Table 2). 
Horizontal eye movement drift in the center and right posi-
tion correlated significantly with mSST and bimanual GPT 
z-scores.
Quick-Phase Velocity of Gaze-Holding Nystagmus and 
Saccadic Intrusions
During VOG recordings saccadic intrusions, such as saccadic 
pulses (Table S2 in Supplementary Material), were found signifi-
cantly more often in patients than in controls in every position but 
the down position (center 0.76 (0.55 [0.48–1.05]) in GD3 and 0.5 
(0.3 [0.24–0.57]) in controls p = 0.033; left 0.64 (0.43 [0.35–0.8]) 
in GD3 and 0.26 (0.16 [0.18–0.34]) in healthy controls p = 0.007; 
right 1.04 (0.54 [0.62–1.2]) in GD3 and 0.56 (0.3 [0.3–0.64]) in 
controls right p = 0.016) (mean (±SD [95% CIs of the mean])) 
(Figures 3B,C). This was also true for the quick-phase amplitude, 
expressed as a 2D vector defined by vertical and horizontal com-
ponents of the eye movement (center: p = 0.008, left: p = 0.044, 
right: p = 0.011) (Figure 3D).
Quick-phase velocity differed significantly in the central 
position with the gaze straight ahead, but not in other positions 
(p =  0.028). Frequency of the quick phases correlated strongly 
with SARA and mSST, but not with bimanual GPT scores, as well 
as with age of onset and disease duration. It also correlated with 
slopes of vertical saccades (Table 2).
Optokinetic Nystagmus
Upward, rightward, and leftward OKN slow phases differed 
significantly across groups tested. Horizontal PV of rightward 
and leftward quick OKN phases differed significantly between 
patients and controls.
Vestibular System: Angular VOR
Mean gain (eye velocity/head velocity to the right and to the left) 
at 60 ms was 0.66 (0.37, [0.49–0.83]) (mean (±SD [95% CIs of 
the mean])) in patients and 1.1 (0.12, [1.04–1.14]) in controls 
(p  <  0.001) (Figure  4; Table S2 in Supplementary Material). 
Correlation analysis showed strong associations between the VOR 
to both sides, but predominantly for rightwards head movement 
(eye movement leftward) and all clinical scores. VOR was also 
significantly correlated with the slopes of vertical saccades and 
downward saccades, but not with upward or horizontal saccades 
(Table 2).
Disease Characteristics
Scale for the Assessment and Rating of Ataxia and mSST were 
significantly associated with disease duration, but not age at onset 
(Table 2). Horizontal eye movement drift in all positions but left 
was significantly associated with age at disease onset, but not with 
duration. This was also true for vertical eye movement drift in 
the left and down position. Gain of upward smooth pursuit cor-
related with disease duration and age at onset. Disease duration 
and age at onset had no relation to horizontal smooth pursuit and 
horizontal aVOR.
longitudinal Oculomotor analysis
Vertical upward and downward smooth pursuit gains at 0.1 Hz, 
but not 0.2  Hz decreased significantly over 1  year. No other 
significant changes in clinical neurological scales or in saccades 
were observed (Table S2 in Supplementary Material). VOR to the 
right showed a trend to improvement after one year (Table S2 in 
Supplementary Material). VOR profiles were consistent over time 
(Figure 5).
TaBle 2 | Correlations of clinical rating scales, disease characteristics, and selected oculomotor parameters in Gaucher disease type 3 patients.
Disease 
duration
iQ Peak velocity 
of downward 
saccades
Duration 
of vertical 
saccades
gaze-holding  
(slow-phase 
velocity)
Quick 
phases  
(2D vector)
gain of 
upward 
smooth 
pursuit 
gain of 
downward 
smooth 
pursuit
gain of 
horizontal 
smooth 
pursuit
gain of 
horizontal 
aVOr
gain of 
horizontal aVOr 
to the right
slopes of 
vertical 
saccades
slopes of 
horizontal 
saccades
SARA ρ = 0.588, 
p = 0.027
ρ = −0.779, 
p = 0.001
ρ = −0.752, 
p < 0.0005
ρ = 0.806, 
p < 0.001
Vertical component 
in the center: 
ρ = −0.803, 
p = 0.001
Center 
frequency: 
ρ = 0.676, 
p = 0.008
NS 0.1 Hz NS ρ = −0.63, 
p = 0.016
ρ = −0.614, 
p = 0.009
NS NS
Vertical component 
down: ρ = −0.772, 
p = 0.001
ρ = 0.563, 
p = 0.036
mSST ρ = 0.536, 
p = 0.048
ρ = −0.804, 
p = 0.001
ρ = −0.611, 
p = 0.003
ρ = 0.700, 
p < 0.0005
Vertical component 
in the center: 
ρ = −0.804, 
p = 0.002
Center 
frequency: 
ρ = 0.688, 
p = 0.013
NS 0.1 Hz NS ρ = −0.725, 
p = 0.003
ρ = −0.677, 
p = 0.008
NS NS
Vertical component 
down: ρ = −0.609 
p = 0.036
ρ = 0.538, 
p = 0.047
Horizontal 
component in the 
center: ρ = 0.694, 
p = 0.01 
Horizontal 
component 
right: ρ = 0.705, 
p = 0.01
Bimanual 
GPT 
z-scores 
(dominant 
vs. non-
dominant 
hand)
NS ρ = −0.785, 
p = 0.004
ρ = −0.649, 
p = 0.005
ρ = 0.558, 
p = 0.02
Vertical component 
in the center: 
ρ = −0.809, 
p = 0.003
NS NS NS Dominant 
hand:
0.1 Hz: 
ρ = −0.627, 
p = 0.039
0.2 Hz: 
ρ = −0.773, 
p = 0.005
ρ = −0.666, 
p = 0.004
ρ = −0.918, 
p < 0.001
NS NS
Horizontal 
component 
right: ρ = 0.673, 
p = 0.023
Non-
dominant 
hand:
0.1 Hz: NS, 
0.2 Hz: 
ρ = −0.606, 
p = 0.048
Disease 
duration
– NS NS NS NS Down: 
frequency
0.2 Hz NS NS NS NS NS NS
ρ = 0.527, 
p = 0.03
ρ = 0.439, 
p = 0.047
(Continued )
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Disease 
duration
iQ Peak velocity 
of downward 
saccades
Duration 
of vertical 
saccades
gaze-holding  
(slow-phase 
velocity)
Quick 
phases  
(2D vector)
gain of 
upward 
smooth 
pursuit 
gain of 
downward 
smooth 
pursuit
gain of 
horizontal 
smooth 
pursuit
gain of 
horizontal 
aVOr
gain of 
horizontal aVOr 
to the right
slopes of 
vertical 
saccades
slopes of 
horizontal 
saccades
Age at 
onset
– NS NS NS Vertical component 
left: ρ = −0.555, 
p = 0.021
Center: peak 
velocity
0.1 Hz: 
ρ = 0.435, 
p = 0.049
NS NS NS NS NS NS
Vertical component 
down: ρ = −0.579, 
p = 0.015
ρ = −0.661, 
p = 0.004
0.2 Hz: 
ρ = 0.552, 
p = 0.009
Horizontal 
component center: 
ρ = −0.713, 
p = 0.001
Horizontal 
component right: 
ρ = −0.512, 
p = 0.036
Horizontal 
component down: 
ρ = −0.804, 
p < 0.001
Slopes of 
downward 
saccades
NS ρ = −0.720, 
p = 0.005
– – Vertical component 
in the center: 
ρ = −0.559, 
p = 0.03
Center: 
frequency
NS NS NS ρ = −0.556, 
p = 0.017
ρ = −0.632, 
p = 0.005
– NS
Vertical component 
left: ρ = −0.625, 
p = 0.013
ρ = 0.511, 
p = 0.051
Slopes of 
vertical 
saccades
NS ρ = −0.740, 
p = 0.002
– – Vertical component 
in the center: 
ρ = −0.733, 
p = 0.001
Center: 
frequency
NS NS NS ρ = −0.632, 
p = 0.005
ρ = −0.767, 
p < 0.001
– NS
Vertical component 
left: ρ = −0.663, 
p = 0.004
ρ = 0.674, 
p = 0.003
Horizontal 
component right: 
ρ = −0.513, 
p = 0.035
Vertical component 
down: ρ = −0.544, 
p = 0.024
TaBle 2 | Continued
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Disease 
duration
iQ Peak velocity 
of downward 
saccades
Duration 
of vertical 
saccades
gaze-holding  
(slow-phase 
velocity)
Quick 
phases  
(2D vector)
gain of 
upward 
smooth 
pursuit 
gain of 
downward 
smooth 
pursuit
gain of 
horizontal 
smooth 
pursuit
gain of 
horizontal 
aVOr
gain of 
horizontal aVOr 
to the right
slopes of 
vertical 
saccades
slopes of 
horizontal 
saccades
Slopes of 
horizontal 
saccades
NS NS NS NS NS NS NS NS NS NS NS NS –
Age – NS NS NS Horizontal 
component straight 
ahead: ρ = −0.498, 
p = 0.042
NS 0.1 Hz: 
ρ = 0.510, 
p = 0.018
0.2 Hz: 
ρ = 0.466, 
p = 0.033
0.1 Hz: 
ρ = 0.425, 
p = 0.055;
NS NS NS NS
Horizontal 
component in 
the left position: 
ρ = −0.618, 
p = 0.008
0.2 Hz: 
ρ = 0.554, 
p = 0.009
0.2 Hz: NS
Horizontal 
component in the 
down position: 
ρ = −0.651, 
p = 0.005
Only significant results are shown.
GPT, Grooved Pegboard Test; mSST, modified Severity Scoring Tool; NS, not significant; OKN, optokinetic nystagmus; p, level of significance; ρ, Spearman correlation coefficient; VOR, vestibulo-ocular reflex; SARA, Scale for the 
Assessment and Rating of Ataxia.
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FigUre 2 | Continued
FigUre 2 | Relationships between vertical and downward saccade 
characteristics and clinical rating scores and slopes of saccadic peak 
duration vs. amplitude of horizontal and vertical saccades. (a) Duration of 
vertical saccades in response to 20° stimulus and modified Severity Scoring 
Tool (mSST). The line has R2 of 0.836 and the variables are significantly 
associated with p < 0.0005. (B) Peak velocity (PV) of vertical saccades in 
response to 20° stimulus and Scale for the Assessment and Rating of Ataxia 
(SARA). The line has R2 of 0.468 and the variables are significantly associated 
with p = 0.001. (c) PV of downward saccades in response to 20° stimuli and 
bimanual z-scores of the grooved pegboard test. The line has R2 of 0.382 
and the variables are significantly associated with p = 0.005.
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No significant longitudinal changes in disease progression, 
as assessed by the clinical rating scales SARA, mSST, and GPT 
z-scores for visuo-manual dextricity, were found. Regarding 
individual progression, patients 2, 7, 9, and 10 worsened and 
patients 1 and 8 improved; the rest remained stable.
DiscUssiOn
This study evaluated the comprehensive ocular motor and ves-
tibular function of a sizable international cohort of patients with 
GD3. It related this function to their overall clinical state in a 
systematic and standardized manner.
The major findings in this study are as follows:
First, gaze-holding function was compromised in some 
patients, which might indicate a cerebellar dysfunction, 
mainly of the flocculus, and/or dysfunction of the neuronal 
integrator (17).
Second, PV of downward saccades and duration of vertical 
saccades as well as gains in horizontal aVOR correlated signifi-
cantly with the patients’ clinical status assessed by SARA, mSST, 
and the GPT. Therefore, these easily quantifiable oculomotor 
and vestibular parameters may be used as biomarkers for future 
studies.
Third, horizontal aVOR was impaired in all patients and 
showed consistent patterns over time in patients evaluated 
longitudinally.
Fourth, longitudinal analysis did not show significant 
changes over time, except for a deterioration of vertical 
smooth pursuit.
Topo-anatomical findings suggest that multiple areas in the 
brainstem and cerebellum are involved in patients with GD3: pon-
tine paramedian reticular formation (PPRF), rostral interstitial 
nucleus of the medial longitudinal fascicle (riMLF), motoneurons 
of the abducens nucleus, cerebellum (mainly the flocculus), and 
the vestibular system. For typical clinical ocular motor findings 
in patients with GD3, see Video S1 in Supplementary Material of 
patient 9 on the webpage.
saccades (clinical-anatomical 
association)
Peak velocity and duration of vertical and downward saccades 
were the most sensitive and robust oculomotor parameters 
because they were strongly associated with all applied clinical 
rating scores. They reflect the function of the burst neurons in 
riMLF, since the instantaneous firing rate of these neurons closely 
correlates with instantaneous eye velocity (18). Slopes of linear 
regression fit for vertical and downward saccades also correlated 
FigUre 3 | Fixation with the gaze straight ahead and gaze-holding in eccentric positions in patients and controls. (a) Slow-phase velocity (SPV) of eye movement 
drift and gaze-evoked nystagmus. Blue represents GD3 patients, green represents healthy controls. Negative values represent direction (vertical, leftwards and 
vertical downwards). (B) Frequency of the 2D vector of quick phases in the respective positions. (c) Peak velocity of the 2D vector of quick phases in respective 
positions. (D) Amplitude of the 2D vector of quick phases in respective positions. Blue represents the fixation with the gaze straight ahead. Green represents the 
gaze-holding to the left. Khaki represents the gaze-holding to the right. Purple represents the gaze-holding in the down position. The length of the boxes indicates 
the interquartile space (P25–P75); the horizontal line into the box represents the median (P50), and the whiskers indicate the adjacent values. The circles indicate the 
outliers and the stars represent an extreme value.
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with the neurological involvement; however, this parameter was 
not related to all neurological assessments and it had a lower 
significance compared to the abovementioned parameters. 
Interestingly, slopes of horizontal and upward saccades, calcu-
lated as peak duration (amplitude/PV) vs. amplitude were not 
significantly associated with any of the clinical measures, perhaps 
because of both a ceiling level of horizontal saccades reflecting 
advanced disease and upward saccades being relatively spared by 
the disease process. The latter is probably caused by calretinin-
positive input from premotor centers, interstitial nucleus of 
Cajal (INC), riMLF, and y-group in upgaze, but not in downgaze 
pathways (19–21). Calretinin is a calcium-binding protein, and 
in combination with parvalbumin and perineuronal nets can 
help identify and analyze the upgaze vs. downgaze ocular motor 
disturbances in other lysosomal diseases, such as Niemann–Pick 
disease type C (22).
Moreover, because the riMLF innervates the upgaze moto-
neurons bilaterally, but downgaze motoneurons ipsilaterally, 
the latter are more susceptible to functional disturbances (23). 
Vertical, especially downward, saccades mirrored gaze-holding 
and aVOR, systems which also degenerate during the disease. 
However, in contrast to horizontal saccades, these systems do not 
seem to trigger a ceiling effect and therefore might potentially 
serve as biomarkers of disease progression. The minor vertical 
saccade impairment went hand-in-hand with the gaze-holding 
deficits in the vertical plane. The most spared upward saccades 
resulted in the presence of upbeat quick phases. Horizontal sac-
cadic deficits result in an absence of all horizontal quick phases 
(including optokinetic and vestibular ones), as was shown in 
a prior publication (6). Our study confirms this finding, even 
though there was still a horizontal component to the movement. 
This might be explained by a cross-coupling mechanism between 
the vertical and horizontal saccadic systems (24).
Bilateral abduction deficits suggest an impairment of abducens 
motoneurons. Thus, patients suffer more pronounced impairment 
of the abducens nucleus than of the PPRF with burst neurons for 
horizontal saccades, which leads to an isolated saccadic impair-
ment. The common feature of these patients is bilateral esotropia, 
which is further accentuated by convergence. Notably, these 
patients were all homozygous for the L444P mutation.
The prolonged latency of horizontal saccades indicates an 
impairment of initiation of reflexive saccades that can be also 
FigUre 4 | Video-head impulse test (vHIT) to assess the angular vestibulo-ocular reflex (aVOR) in healthy controls (HC) and patients with GD3. (a,B) vHIT to the 
right, (c,D) vHIT to the left. The gray curves represent a mean of 10 ± 5 vHIT of a particular HC and a patient, respectively. The thick blue line represents the groups’ 
mean eye movement and the thick gray and black lines represent the groups’ mean head movement. Mean gain (eye velocity/head velocity to the right and to the 
left) of the aVOR by 60 ms was 0.66 (0.37, [0.49–0.83]) (mean (± SD [95% CIs of the mean])) in patients and 1.1 (0.12, [1.04–1.14]) in controls (p < 0.001).
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related to the PPRF disturbance. Since GD3 patients exhibit defi-
cits of reflexive saccades, quick phases, and vestibular movements 
per se, head thrusts do not represent oculomotor apraxia, defined 
as voluntary eye movement failure, but probably represent an 
attempted adaptive strategy to facilitate change in gaze, as you 
can see in Video S2 in Supplementary Material (25). We observed 
the same variation of saccadic PV in the phase plane plots of eye 
position vs. velocity as seen in a previous study (4). This is due 
to the malfunction of omnipause neurons in the pontine nucleus 
raphe interpositus that control saccade generation by inhibiting 
the activity of burst neurons (26).
Vestibulo-Ocular reflex
We have observed similar velocity “wiggling” during the perfor-
mance of VOR, with each patient having a unique VOR pattern, 
as you can see in the Figure 5. A trajectory analysis revealed 
substantial decelerations of eye velocity, which appeared 
variably during the VOR course. A pathological VOR gain 
has been previously described in 2 siblings with GD3 (6). The 
pathological VOR is probably caused by a complex involve-
ment of abducens nuclei, the medial vestibular region and/or 
vestibulo-cerebellum, accounting for reduced VOR gains, and 
by the PPRF, responsible for an absence of re-fixation saccades. 
Moreover, since some patients were not able to counteract 
the head movement at all, they generated a delayed saccadic 
movement to the fixation target; thus, the disturbance of the 
omnipause neurons might also explain transient decelerations 
during the VOR course.
smooth Pursuit
In terms of smooth pursuit, only downward gain differed between 
adult patients and controls, being better in patients. This might 
be explained by riMLF and/or cerebellar impairment, leading 
to diminished saccadic intrusions during the smooth pursuit. 
Smooth pursuit seemed to be relatively spared by the disease 
process, although downward and upward smooth pursuit both 
significantly worsened at follow-up. Also, downward gain cor-
related significantly with the mSST and SARA scores. Therefore, 
downward gain might be a suitable biomarker, despite its age-
dependence. The low values of the vertical smooth pursuit gain 
are based on the fact that orientation in the horizontal plane is 
more important than in the vertical one for humans as bipedal 
animals. This was also reflected in the negative association 
between horizontal smooth pursuit and the GPT, since both 
saccades and smooth pursuit are needed for the performance of 
complex tasks in daily life.
FigUre 5 | Longitudinal development of the vestibulo-ocular reflex (VOR) in patients with GD3. Note the variety of patterns of a VOR impairment which remains 
stable over time. The stained curves indicate the eye movement with every curve representing a mean of 10 ± 5 HIT of a particular patient. Grey depicts the head 
movement.
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gaze-holding
Gaze-holding deficits were found in fixation both with gaze 
straight ahead and gaze-holding in eccentric positions, suggest-
ing that neural integrators and the vestibulo-cerebellum might 
be involved (see also Figure  3). The gaze-holding nystagmus 
had a predominant vertical upbeat component, with a minor 
horizontal component, seen also in correlations with all clinical 
rating scores. This reinforces the possibility of cross-coupling 
mechanism, as inactivation of PPRF also leads to saccades with 
curved trajectories in monkeys (27).
The eye motility deficits seen in some patients might be gaze-
paretic in nature, related to an abnormal innervation pulse to the 
lateral recti muscles, which are not able to abduct the eyes due to 
the abducens dysfunction. Eleven patients were diagnosed with 
convergent squint and in three cases strabismus was surgically 
corrected. Mild amblyopia was seen in 10 out of 11 patients with 
strabismus. The convergent squint might be caused by an impair-
ment of visual fusional mechanism; however, it might be related 
to the impairment of the cerebellar flocculus and, in the associa-
tion with dysmetric saccades, also of the oculomotor vermis (28).
Esotropia might contribute to the fixation deficits seen in our 
patients, since they are well known in strabismic individuals, 
especially in those with amblyopia (29–32). The primary-position 
upbeat nystagmus is probably related to the paramedian medulla 
(33) (especially in light of the impaired VOR) involvement. 
Nevertheless, vertical eye movements in terms of vertical gaze-
holding nystagmus might also be generated to compensate for the 
horizontal eye movement palsy due to impairment of abducens 
nucleus. Oculomotor systems correlated variably with disease 
duration and/or age of onset, reflecting a variable rate of involve-
ment of neural structures during the course of disease.
longitudinal analysis
We did not see any disease progression in the saccade analysis 
as a group, but the data varied. This also accounts for the lack 
of correlation between vertical and horizontal saccadic systems. 
Angular VOR to the right showed a tendency to improvement at 
follow-up; the VOR to the left remained quite stable. Moreover, 
patients showed unique patterns with variable velocity changes in 
the aVOR course. In contrast to saccades, downward and upward 
smooth pursuit worsened over 1  year. This demonstrates that 
in GD3 oculomotor deficits progress to different extents and at 
different rates.
limitations of the study
The sample size for the longitudinal analysis is small, with a short 
follow-up length due to the logistical peculiarities and disease 
rarity, meaning that these analyses might be underpowered. Also, 
the further vestibular tests, such as vertical semicircular canal 
evaluation and vestibular evoked myogenic potentials (VEMP) 
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ViDeO s1 | Thorough ocular motor examination of a patient 9.
ViDeO s2 | Impaired voluntary saccades in a patient 1, compensated by head 
thrusts.
examination, testing the otolith function were not performed, 
mainly due to the logistical reasons. As some patients were 
children and/or became fatigued very quickly, some tests were 
not performed due to lack of compliance or physical disability. 
The measurement was monocular, so that movement differences 
between eyes were not assessed.
cOnclUsiOn
In conclusion, our findings suggest a widespread neuronal 
dysfunction, both at brainstem and cerebellar levels. The deficits 
seen in the oculomotor and vestibular examination, particularly 
those that progressed over time, can be used as biomarkers in 
future clinical trials. Future studies evaluating the voluntary sac-
cades, including also absolute number of performed saccades or 
intersaccadic intervals, should be planned to assess the reliability 
of these biomarkers. The otolith function examined by VEMP 
holds promise as another vestibular biomarker, as was shown 
previously. Also, a compact binocular testing battery to minimize 
the effect of fatigue should be performed in clinical trials in the 
future. Our clinical experience also suggests performing the VOG 
as early as possible prior to the other clinical tests.
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